Neutrophil percentage-to-albumin ratio as a predictor of In-hospital mortality in infective endocarditis.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-09-01 Epub Date: 2025-09-19 DOI:10.1080/17520363.2025.2562554

Muhammet Mucahit Tiryaki, Cemalettin Yilmaz, Huseyin Sefa Ince, Banu Karaca, Fatma Kayaalti Esin, Tuncay Kiris

{"title":"Neutrophil percentage-to-albumin ratio as a predictor of In-hospital mortality in infective endocarditis.","authors":"Muhammet Mucahit Tiryaki, Cemalettin Yilmaz, Huseyin Sefa Ince, Banu Karaca, Fatma Kayaalti Esin, Tuncay Kiris","doi":"10.1080/17520363.2025.2562554","DOIUrl":null,"url":null,"abstract":"Background: Infective endocarditis (IE) remains a life-threatening condition despite treatment advances. Early identification of high-risk patients is essential. The neutrophil percentage-to-albumin ratio (NPAR) is a novel inflammatory marker linked to poor outcomes in various diseases, but its prognostic value in IE remains unclear. This study aimed to investigate the association between NPAR and in-hospital mortality in patients with IE.Methods: We retrospectively analyzed 263 patients diagnosed with IE between January 2009 and January 2024 at a tertiary care center. Clinical, laboratory, and echocardiographic data were collected. NPAR was calculated as (Neutrophil %/Albumin [g/dL]). Predictors of mortality were identified using LASSO-based logistic regression, and a nomogram was constructed to illustrate predictive performance.Results: In-hospital mortality occurred in 59 patients (22.4%). NPAR was significantly higher among non-survivors (median: 0.335 vs. 0.228, p < 0.001). High NPAR ( >0.274) was independently associated with in-hospital mortality (OR: 6.70, 95% CI: 3.07-15.61, p < 0.001), along with large vegetation and diabetes mellitus. High NPAR showed good discriminative power (AUC = 0.72, 95% CI: 0.66-0.79, p < 0.001).Conclusion: High NPAR was an independent predictor of in-hospital mortality in IE and may serve as a simple, cost-effective biomarker for early risk stratification.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"867-874"},"PeriodicalIF":2.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477859/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2562554","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Infective endocarditis (IE) remains a life-threatening condition despite treatment advances. Early identification of high-risk patients is essential. The neutrophil percentage-to-albumin ratio (NPAR) is a novel inflammatory marker linked to poor outcomes in various diseases, but its prognostic value in IE remains unclear. This study aimed to investigate the association between NPAR and in-hospital mortality in patients with IE.

Methods: We retrospectively analyzed 263 patients diagnosed with IE between January 2009 and January 2024 at a tertiary care center. Clinical, laboratory, and echocardiographic data were collected. NPAR was calculated as (Neutrophil %/Albumin [g/dL]). Predictors of mortality were identified using LASSO-based logistic regression, and a nomogram was constructed to illustrate predictive performance.

Results: In-hospital mortality occurred in 59 patients (22.4%). NPAR was significantly higher among non-survivors (median: 0.335 vs. 0.228, p < 0.001). High NPAR ( >0.274) was independently associated with in-hospital mortality (OR: 6.70, 95% CI: 3.07-15.61, p < 0.001), along with large vegetation and diabetes mellitus. High NPAR showed good discriminative power (AUC = 0.72, 95% CI: 0.66-0.79, p < 0.001).

Conclusion: High NPAR was an independent predictor of in-hospital mortality in IE and may serve as a simple, cost-effective biomarker for early risk stratification.

查看原文本刊更多论文

中性粒细胞百分比-白蛋白比作为感染性心内膜炎住院死亡率的预测因子。

背景：尽管治疗进展，感染性心内膜炎（IE）仍然是一种危及生命的疾病。早期识别高危患者至关重要。中性粒细胞百分比与白蛋白比率（NPAR）是一种新的炎症标志物，与各种疾病的不良预后有关，但其在IE中的预后价值尚不清楚。本研究旨在探讨NPAR与IE患者住院死亡率之间的关系。方法：我们回顾性分析了2009年1月至2024年1月在三级保健中心诊断为IE的263例患者。收集临床、实验室和超声心动图资料。NPAR计算为（中性粒细胞%/白蛋白[g/dL]）。使用基于lasso的逻辑回归确定死亡率的预测因子，并构建了一个nomogram来说明预测性能。结果：住院死亡59例（22.4%）。非幸存者的NPAR显著更高（中位数：0.335 vs. 0.228, p 0.274）与住院死亡率独立相关（OR: 6.70, 95% CI: 3.07-15.61, p p）结论：高NPAR是IE住院死亡率的独立预测因子，可作为早期风险分层的简单、经济有效的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.